Boehringer Ingelheim’s AI Investment Is Welcome News For The UK
After numerous big pharma companies paused or scrapped UK investments last year, the German firm’s new AI research center is a shot in the arm for the country's sector.
Scrip - April 20, 2026

Harbinger Raises $100M, Presents New Data For Cancer Tests At AACR
Harbinger Health showed off more positive data for its multi-cancer test platform at AACR after announcing $100M funding to help commercialize its first product.
Medtech Insight - April 20, 2026

Data Governance: Do You Have What It Takes to Realize the Promise of AI?
Genedata experts argue AI's promise in drug discovery depends less on algorithms than on data quality, and most organizations' data governance is not yet fit for purpose.
In Vivo - April 20, 2026

ANI Bolsters US Generics Offering With Two Launches
Following two recent generic approvals from the US Food and Drug Administration, ANI Pharmaceuticals continues to widen its generic portfolio with the addition of carbamazepine and isosorbide mononitrate.
Generics Bulletin - April 20, 2026

Lupin Follows Sandoz, Sun In Antitrust Suit Settlement; $30m For Humana
Lupin has followed Sandoz and Sun Pharma in settling antitrust litigation on alleged price-fixing. This $30m settlement with US insurance giant Humana denies all allegations and does not imply admission of liability, but could more settlements be in the offing?
Generics Bulletin - April 20, 2026

Another One Bites The Dust: Iterum Shuts Shop As Antibiotic Woes Drag On
High post-approval costs, weak returns and low initial uptake continue to weigh on antibiotics.
In Vivo - April 20, 2026

Reddy’s Brazil Setback Signals Tougher Semaglutide Path
Brazil’s regulator has rejected three GLP-1 filings, including Dr Reddy’s semaglutide bid, despite fast-track measures to boost supply. The setback comes as patent expiries, surging demand and new investment intensify the race for Latin America’s biggest obesity market.
Generics Bulletin - April 20, 2026

Pipeline Watch: Seven Approvals And A Phase III Readout
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 20, 2026

AstraZeneca Builds COPD Case For Tozorakimab With Third Positive Phase III Trial
With MIRANDA joining earlier Phase III wins, AstraZeneca is building a consistent evidence base for tozorakimab that analysts say could expand biologic use beyond currently targeted COPD populations.
Scrip - April 20, 2026

Medtronic, Pulnovo Join Forces On Pulmonary Denervation After $100M Financing
Medtronic has led a $100m financing round for the Chinese cardiopulmonary firm, as the two companies said they will explore “commercial synergies.”
Medtech Insight - April 20, 2026

The Chemist Who Wants To Reprogram Drug Discovery
Lee Cronin wants to build the AWS of molecular discovery. His Glasgow-based startup Chemify is making the molecules to prove it.
In Vivo - April 20, 2026

Alphamab Pursues Differentiated Approach To Next-Gen ADCs
In the space of antibody-drug conjugate, Alphamab Oncology’s CEO talks to Scrip about views on future partnership strategies and differentiation approaches for developing next-generation molecules.
Scrip - April 20, 2026